A cryptocurrency-fueled gray-market peptide market has surpassed a $100 million annual run rate as demand for lower-cost weight loss drugs continues to grow, according to a June 4 Chainalysis report. The report found that some Chinese chemical manufacturers that once supplied fentanyl and amphetamine precursors to drug cartels have shifted into selling these unregulated weight-loss and cosmetic peptides directly to US consumers, amid the rise in demand.
The findings track with what Novo Nordisk CEO and President Mike Doustdar described in May as a US “peptide craziness,” crediting that same enthusiasm with helping drive more than 2 million prescriptions for the Wegovy pill in the months since its January launch. But the wellness peptides fueling the gray market are distinct from brand-name GLP-1s that underwent years of safety and efficacy trials, and ECRI and the Institute for Safe Medication Practices have raised concerns about compounded peptide formulations advertised for building muscle, slowing aging, aiding injury recovery and boosting immune support due to a lack of evidence on their safety in humans.
Here are five notes from the report:
- Cryptocurrency inflows to gray-market peptide vendors have grown for six consecutive quarters and are on pace to cross a $100 million annual run rate in 2026, up from roughly $1 million a quarter in 2024.
- Independent safety testing has dropped sharply as retail demand has grown. The report found spending on third-party purity verification fell an estimated 88% per buyer even as testing volume at one Czech lab increased, with buyers instead relying on vendor-supplied certificates that often don’t screen for sterility.
- Two case studies named in the report, Shanghai Sigma Audley New Material Technology and Bigreat Technology, were previously identified as fentanyl and amphetamine precursor suppliers to cartels and darknet vendors before rebranding to sell peptides to retail buyers using the same contact information.
- The gray market has also moved into brick-and-mortar retail. At least two Brooklyn bodegas openly sold vials labeled as retatrutide with no age verification or prescription required, according to a July 2 CBS News report. The vendor’s purity certificates, which claimed third-party lab testing, were confirmed fake by the lab whose name appeared on them, and the retatrutide sample was mislabeled data for a different drug, tirzepatide.
- Chainalysis said the shift reflects how illicit chemical suppliers are adapting to law enforcement pressure on the precursor trade by moving into a less-regulated, more profitable direct-to-consumer market that doesn’t reliably screen buyers, including minors.
The findings add to a string of unapproved peptides that have reached the mainstream. In December 2024, the FDA sent warning letters to Xcel Peptides, Swisschems, Summit Research and Prime Peptides over unapproved GLP-1 products, including semaglutide, tirzepatide and retatrutide, and separately warned about compounded weight loss drugs after finding contamination at an Ontario, Calif., compounding facility. That same month, Tennessee authorities uncovered more than 300 vials of counterfeit semaglutide and tirzepatide during a raid tied to an alleged seller of knockoff weight loss drugs, with testing showing one counterfeit sample was mostly water.
More recently, the FDA’s own oversight of peptides has drawn scrutiny. Ahead of a July 23-24 meeting on whether seven widely sold peptides, including BPC-157 and TB-500, should be added to the agency’s approved list of compounding substances, HHS reshaped the advisory panel, which now leans on physicians who run wellness, longevity and regenerative medicine clinics rather than the university researchers who staffed prior panels, with several panelists holding direct financial ties to the peptide and regenerative medicine industry.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.